Cure My Disease

Don't miss your cure!

 Log in / Sign up

HIV patients may ditch daily pills for monthly shots

NCT ID NCT02938520

Ongoing Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether people with HIV who are already well-controlled on daily pills can switch to a monthly injection of two drugs (cabotegravir and rilpivirine) and stay just as healthy. About 630 adults whose virus is suppressed on a standard three-drug pill regimen will either continue their daily pills or switch to the monthly shots. The goal is to see if the injections are as good at keeping the virus undetectable over 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

cabotegravir and rilpivirine (injectable long-acting formulation)

What this could lead to

If successful, this could offer people with HIV a convenient monthly injection instead of daily pills, making it easier to stay on treatment and maintain viral suppression.

What could go wrong

This is a Phase 3 trial, but the injections may cause injection-site reactions or fail to suppress the virus in some people. Long-term safety and effectiveness beyond 48 weeks are still being studied.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

  • GSK Investigational Site

    Long Beach, California, 90813, United States

  • GSK Investigational Site

    Los Angeles, California, 90019, United States

  • GSK Investigational Site

    Los Angeles, California, 90027, United States

  • GSK Investigational Site

    Augusta, Georgia, 30912-3130, United States

  • GSK Investigational Site

    Macon, Georgia, 31201, United States

  • GSK Investigational Site

    Austin, Texas, 78705, United States

  • GSK Investigational Site

    Bellaire, Texas, 77401, United States

  • GSK Investigational Site

    Dallas, Texas, 75246, United States

  • GSK Investigational Site

    Fort Worth, Texas, 76104, United States

  • GSK Investigational Site

    Aichi, 460-0001, Japan

  • GSK Investigational Site

    Osaka, 540-0006, Japan

  • GSK Investigational Site

    Tokyo, 162-8655, Japan

  • GSK Investigational Site

    Kazan', 420061, Russia

  • GSK Investigational Site

    Kemerovo, 650056, Russia

  • GSK Investigational Site

    Krasnodar, 350015, Russia

  • GSK Investigational Site

    Lipetsk, 398043, Russia

  • GSK Investigational Site

    Moscow, 115035, Russia

  • GSK Investigational Site

    Oryol, 302040, Russia

  • GSK Investigational Site

    Saint Petersburg, 190020, Russia

  • GSK Investigational Site

    Saint Petersburg, 193167, Russia

  • GSK Investigational Site

    Saint Petersburg, 196645, Russia

  • GSK Investigational Site

    Saratov, 410009, Russia

  • GSK Investigational Site

    Smolensk, 214006, Russia

  • GSK Investigational Site

    Toliyatti, 445846, Russia

  • GSK Investigational Site

    Yekaterinburg, 620102, Russia

  • GSK Investigational Site

    Bloemfontein, 9301, South Africa

  • GSK Investigational Site

    Cape Town, 7925, South Africa

  • GSK Investigational Site

    Durban, 4052, South Africa

  • GSK Investigational Site

    Durban, 4091, South Africa

  • GSK Investigational Site

    Johannesburg, 2113, South Africa

  • GSK Investigational Site

    Middelburg, 1055, South Africa

  • GSK Investigational Site

    Pretoria, 0087, South Africa

  • GSK Investigational Site

    Ferrol, 15405, Spain

  • GSK Investigational Site

    Granada, 18016, Spain

  • GSK Investigational Site

    La Laguna Santa Cruz, 38320, Spain

  • GSK Investigational Site

    Madrid, 28041, Spain

  • GSK Investigational Site

    Madrid, 28046, Spain

  • GSK Investigational Site

    Murcia, 30003, Spain

  • GSK Investigational Site

    San SebastiAn de Los Rey, 28702, Spain

  • GSK Investigational Site

    Santa Cruz de Tenerife, 38010, Spain

  • GSK Investigational Site

    Santander, 39008, Spain

  • GSK Investigational Site

    Birmingham, B9 5SS, United Kingdom

  • GSK Investigational Site

    Leeds Yorkshire, LS1 3EX, United Kingdom

  • GSK Investigational Site

    London, E1 1BB, United Kingdom